During the last session, Xilio Therapeutics Inc (NASDAQ:XLO)’s traded shares were 2.42 million, with the beta value of the company hitting -0.13. At the end of the trading day, the stock’s price was $0.89, reflecting an intraday loss of -29.91% or -$0.38. The 52-week high for the XLO share is $1.93, that puts it down -116.85 from that peak though still a striking 43.82% gain since the share price plummeted to a 52-week low of $0.50. The company’s market capitalization is $40.73M, and the average intraday trading volume over the past 10 days was 0.39 million shares, and the average trade volume was 542.64K shares over the past three months.
Xilio Therapeutics Inc (XLO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. XLO has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Xilio Therapeutics Inc (XLO) registered a -29.91% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -29.91% in intraday trading to $0.89, hitting a weekly high. The stock’s 5-day price performance is -17.58%, and it has moved by 2.72% in 30 days. Based on these gigs, the overall price performance for the year is 31.11%. The short interest in Xilio Therapeutics Inc (NASDAQ:XLO) is 0.38 million shares and it means that shorts have 0.46 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 87.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, XLO is trading at a discount of -686.52% off the target high and -686.52% off the low.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Statistics show that Xilio Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Xilio Therapeutics Inc (XLO) shares have gone down -10.00% during the last six months, with a year-to-date growth rate more than the industry average at 58.99% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -44.91%. While earnings are projected to return 59.04% in 2025.
XLO Dividends
Xilio Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Xilio Therapeutics Inc insiders own 39.06% of total outstanding shares while institutional holders control 28.36%, with the float percentage being 46.54%. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the largest shareholder of the company, while 34.0 institutions own stock in it. As of 2024-06-30, the company held over 3.79 million shares (or 13.5618% of all shares), a total value of $3.59 million in shares.
The next largest institutional holding, with 3.0 million shares, is of ROCK SPRINGS CAPITAL MANAGEMENT LP’s that is approximately 10.7595% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.85 million.
Also, the Mutual Funds coming in first place with the largest holdings of Xilio Therapeutics Inc (XLO) shares are Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 739.56 shares. This amounts to just over 1.68 percent of the company’s overall shares, with a $0.66 million market value. The same data shows that the other fund manager holds slightly less at 181.63, or about 0.41% of the stock, which is worth about $0.16 million.
